ClinicalTrials.gg
Active, not recruitingNCT06260163QUASAR JrUpdated Nov 3, 2026

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Guselkumab Subcutaneous and Guselkumab Intravenous in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 61 sites in 13 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
18th of 28
112 · median 205
Started
2024
with 1 other
Phase 3
15 of 43
2 open now
Primary completion
2027-02
later than 5 of 20 live
Registered
31st of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 15 in phase 3, reaches primary completion later than 5 of the 20 other live ones, and was the 31st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight greater than or equal to (>=) 10 kilogram (kg) at the time of consent for screening
  • A pathology report to support a documented diagnosis of Ulcerative Colitis (UC) must be available in the source documents. There is no maximum duration for which a participant needs to be diagnosed with UC. If the pathology report to support a documented diagnosis of UC is not available in the source documents, the screening endoscopy with (obtained within 3 weeks before first study intervention administration) needs to support the diagnosis of UC.
  • Moderately to severely active UC, defined by a baseline modified Mayo (without physician's global assessment) score of 5 through 9 inclusive, with a screening Mayo endoscopy subscore >= 2 as determined by a central review of the video of the endoscopy
  • Medically stable based on physical examination, medical history, and vital signs, performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator
  • Participants must have had an inadequate response and/or intolerance to biologic therapy and/or conventional therapies or be dependent upon

Exclusion criteria

Exclusion Criteria:

  • Have UC limited to the rectum only or to less than (\<) 20 centimeter of the colon
  • Presence of a stoma
  • Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months of baseline
  • Have severe colitis or have evidence of Crohn's Disease (CD)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Open-label Induction Phase: Guselkumab Intravenously (IV)

    Participants will receive a guselkumab dose IV based on their body weight (BW) during the 12-week open-label induction phase.

    Drug: Guselkumab Intravenous

  • Experimental
    Open-label Induction Phase: Guselkumab Subcutaneously (SC)

    Participants will receive a guselkumab dose SC based on their BW during the 12-week open-label induction phase.

    Drug: Guselkumab Subcutaneous

  • Experimental
    Double-blind Maintenance Phase: Guselkumab Dose Regimen 1

    At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their BW up to Week 56.

    Drug: Guselkumab Subcutaneous

  • Experimental
    Double-blind Maintenance Phase: Guselkumab Dose Regimen 2

    At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their BW up to Week 56.

    Drug: Guselkumab Subcutaneous

  • Experimental
    Open-label Maintenance Phase: Guselkumab SC

    Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 56.

    Drug: Guselkumab Subcutaneous

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Remission at Week 56

    Percentage of participants with clinical remission as assessed by modified Mayo score at Week 56 among participants who were induction responders will be reported. Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.

    Time frame: Week 56

Secondary outcomes

  1. Percentage of Participants with Clinical Response at Week 12

    Percentage of participants with clinical response as assessed by modified Mayo score at Week 12 will be reported. Modified Mayo score is a 3-component (stool frequency, rectal bleeding, and endoscopy subscores) assessment and does not include the physician's global assessment. A decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1.

    Time frame: Week 12

  2. Percentage of Participants with Clinical Remission at Week 12

    Percentage of participants with clinical remission at Week 12 as assessed by modified Mayo score will be reported. Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.

    Time frame: Week 12

  3. Percentage of Participants With Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission at Week 12

    Percentage of participants with PUCAI remission at Week 12 will be reported. It comprises 6 scales and ranges between 0 and 85 points. The scales are abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level. The PUCAI score is calculated as the sum of the 6 subscores. A PUCAI score of less than (\<) 10 indicates remission.

    Time frame: Week 12

  4. Percentage of Participants with Symptomatic Remission at Week 12

    Percentage of participants with symptomatic remission at Week 12 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.

    Time frame: Week 12

  5. United States: Percentage of Participants with Endoscopic Improvement at Week 12

    Percentage of participants with endoscopic improvement as assessed by Mayo endoscopy subscore at Week 12 will be reported. Endoscopic improvement is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

    Time frame: Week 12

  6. European Union: Percentage of Participants with Endoscopic Healing at Week 12

    Percentage of participants with endoscopic healing as assessed by Mayo endoscopy subscore at Week 12 will be reported. Endoscopic healing is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

    Time frame: Week 12

  7. Percentage of Participants with Clinical Response at Week 56

    Percentage of participants with clinical response as assessed by modified Mayo score at Week 56 will be reported. Modified Mayo score is a 3-component (stool frequency, rectal bleeding, and endoscopy subscores) assessment and does not include the physician's global assessment. A decrease from baseline in the modified Mayo score by \>= 30 percent and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1.

    Time frame: Week 56

  8. Percentage of Participants With PUCAI Remission at Week 56

    Percentage of participants with PUCAI remission at Week 56 will be reported. PUCAI comprises of 6 scales and ranges between 0 and 85 points. The scales are: abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level. The PUCAI score is calculated as the sum of the 6 subscores. A PUCAI score of less than (\<) 10 indicates remission.

    Time frame: Week 56

  9. Percentage of Participants with Symptomatic Remission at Week 56

    Percentage of participants with symptomatic remission at Week 56 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.

    Time frame: Week 56

  10. Percentage of Participants with Symptomatic Remission at Week 56 Among Participants who had Symptomatic Remission at Week 12

    Percentage of participants with symptomatic remission at Week 56 among participants who had symptomatic remission at Week 12 will be reported. Symptomatic remission score is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.

    Time frame: Week 56

  11. United States: Percentage of Participants With Endoscopic Improvement at Week 56

    Percentage of participants with endoscopic improvement as assessed by Mayo endoscopy subscore at Week 56 will be reported. Endoscopic improvement is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

    Time frame: Week 56

  12. European Union: Percentage of Participants With Endoscopic Healing at Week 56

    Percentage of participants with endoscopic healing as assessed by Mayo endoscopy subscore at Week 56 will be reported. Endoscopic healing is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.

    Time frame: Week 56

  13. Percentage of Participants Who Achieve Endoscopic Normalization at Week 56

    Percentage of participants who achieve endoscopic normalization with an endoscopy subscore of 0 at Week 56 will be reported.

    Time frame: Week 56

  14. Percentage of Participants Histo-endoscopic Mucosal Improvement at Week 56

    Percentage of participants histo-endoscopic mucosal healing per endoscopy subscore and histologic improvement at Week 56 will be reported. Histologic-endoscopic mucosal healing is defined as achieving a combination of histologic improvement and endoscopic improvement (US) or endoscopic healing (EU) (endoscopy subscore of 0 or 1).

    Time frame: Week 56

  15. Percentage of Participants with Corticosteroid-free Clinical Remission at Week 56

    Percentage of participants with corticosteroid-free clinical remission at Week 56 will be reported. Corticosteroid free clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline (Week 0), and not receiving corticosteroids for at least 8 weeks prior to Week 56

    Time frame: Week 56

  16. Serum Concentration of Guselkumab During Induction Phase

    Serum samples will be analyzed to determine concentrations of guselkumab overtime.

    Time frame: From Week 0 to Week 12

  17. Serum Concentration of Guselkumab During Maintenance Phase

    Serum samples will be analyzed to determine concentrations of guselkumab over time.

    Time frame: From Week 12 to Week 56

  18. Number of Participants with Incidence of Anti-guselkumab Antibodies

    Number of participants with anti-guselkumab antibodies for all study treatment regimens will be assessed.

    Time frame: Up to Week 68

  19. Percentage of Participants with Adverse Events (AEs)

    Percentage of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: Up to Week 68

  20. Percentage of Participants with Serious Adverse Events (SAEs)

    Percentage of participants with SAEs will be reported. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly.

    Time frame: Up to Week 68

  21. Percentage of Participants with AEs Leading to Discontinuation of Study Intervention

    Percentage of participants with AEs leading to discontinuation of study intervention will be reported.

    Time frame: Up to Week 68

07

Study locations

61 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 36 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 15, 2024
StartActual
Jan 19, 2024
Primary completionEst.
Feb 10, 2027
CompletionEst.
Apr 28, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06260163
Responsible party
Sponsor
First posted
Feb 15, 2024
Start date
Jan 19, 2024
Primary completion
Feb 10, 2027 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion